NO20083288L - Konjungat for behandling av tumorer - Google Patents

Konjungat for behandling av tumorer

Info

Publication number
NO20083288L
NO20083288L NO20083288A NO20083288A NO20083288L NO 20083288 L NO20083288 L NO 20083288L NO 20083288 A NO20083288 A NO 20083288A NO 20083288 A NO20083288 A NO 20083288A NO 20083288 L NO20083288 L NO 20083288L
Authority
NO
Norway
Prior art keywords
tumors
treatment
antitumor
conjugate
specific
Prior art date
Application number
NO20083288A
Other languages
English (en)
Norwegian (no)
Inventor
Yongzhang Luo
Qingxin Lei
Guodong Chang
Hao Zhou
Original Assignee
Protgen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protgen Ltd filed Critical Protgen Ltd
Publication of NO20083288L publication Critical patent/NO20083288L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
    • C12N11/089—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
    • C12Y305/03006—Arginine deiminase (3.5.3.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20083288A 2006-01-20 2008-07-24 Konjungat for behandling av tumorer NO20083288L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200610011246A CN101002945B (zh) 2006-01-20 2006-01-20 一种用于肿瘤治疗的新型复合物
PCT/CN2007/000203 WO2007082482A1 (fr) 2006-01-20 2007-01-19 Nouveau composé de traitement de tumeur

Publications (1)

Publication Number Publication Date
NO20083288L true NO20083288L (no) 2008-10-20

Family

ID=38287272

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083288A NO20083288L (no) 2006-01-20 2008-07-24 Konjungat for behandling av tumorer

Country Status (8)

Country Link
US (1) US20100303893A1 (fr)
EP (1) EP1987838B1 (fr)
JP (1) JP2009523433A (fr)
CN (1) CN101002945B (fr)
AU (1) AU2007207267B2 (fr)
CA (1) CA2637687C (fr)
NO (1) NO20083288L (fr)
WO (1) WO2007082482A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012522782A (ja) * 2009-04-03 2012-09-27 ザ・ユニバーシティ・オブ・トレド 医薬のためのプラットフォームとしての、少なくとも１つの保護されたチオール領域を有するｐｅｇ−アルブミン組成物
HUE052285T2 (hu) * 2011-06-06 2021-04-28 Starpharma Pty Ltd Makromolekulák
JP2014521602A (ja) * 2012-04-04 2014-08-28 ポラリス グループ アルギニンデイミナーゼを用いる処置方法
US9506897B2 (en) * 2012-11-16 2016-11-29 Agilent Technologies, Inc. Methods and compositions for improved ion-exchange chromatography
USRE48805E1 (en) 2013-03-06 2021-11-02 Vision Global Holdings Ltd. Method for cancer targeting treatment and detection of arginine using albumin-binding arginine deiminase fusion protein
US9255262B2 (en) * 2013-03-06 2016-02-09 Vision Global Holdings Ltd. Albumin-binding arginine deminase and the use thereof
WO2014151982A2 (fr) 2013-03-15 2014-09-25 Polaris Group Arginine désiminase à réactivité croisée réduite envers les anticorps anti-adi-peg 20 pour le traitement du cancer
WO2015143006A1 (fr) 2014-03-18 2015-09-24 Tdw Group Adi pégylée chimères manipulée et procédés d'utilisation
CN104031261B (zh) * 2014-06-20 2017-10-27 电子科技大学 温敏性共聚物及其水凝胶体系
US10588980B2 (en) * 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
CA2961602A1 (fr) 2014-09-16 2016-03-24 Polaris Group Arginine deiminase a activite heterospecifique reduite vis-a-vis des anticorps anti-adi-cheville 20 pour le traitement du cancer
CN105801870B (zh) * 2016-04-08 2018-08-21 北京华熙海御科技有限公司 一种聚唾液酸-透明质酸复合凝胶的制备方法及所得产品和应用
US12281339B2 (en) 2016-07-05 2025-04-22 Polaris Group Combination cancer immunotherapies with arginine depletion agents
EP3534963B1 (fr) 2016-11-02 2024-04-17 Polaris Group Formulations d'arginine déiminase pegylée
CN108265068B (zh) * 2016-12-31 2021-06-15 江苏众红生物工程创药研究院有限公司 重组精氨酸脱亚胺酶及其产业化制备方法和应用
CN110870869A (zh) * 2018-08-31 2020-03-10 成都夸常奥普医疗科技有限公司 包含糖类营养素和常规无效化合物的药物组合物及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911929A (en) 1986-08-29 1990-03-27 The United States Of America As Represented By The Secretary Of The Navy Blood substitute comprising liposome-encapsulated hemoglobin
AU5858690A (en) * 1989-06-14 1991-01-08 Cetus Corporation Polymer/antibiotic conjugate
JP2900279B2 (ja) 1989-08-02 1999-06-02 株式会社ジャパンエナジー 新規なアルギニンデイミナーゼ、その製造法及び該酵素を有効成分とする制癌剤
JP3209338B2 (ja) * 1990-09-10 2001-09-17 株式会社ジャパンエナジー ポリエチレングリコール修飾アルギニンデイミナーゼおよびその製造法
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US6635462B1 (en) * 1997-05-12 2003-10-21 Phoenix Pharmacologies, Inc. Mutated form of arginine deiminase
US6183738B1 (en) * 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase
US6689762B1 (en) 1998-02-09 2004-02-10 Enzon Pharmaceuticals, Inc. Composition and methods for treatment of HIV infection
ATE245444T1 (de) 1998-02-09 2003-08-15 Enzon Pharmaceuticals Inc Pharmazeutische zusammensetzung, enthaltend peg- asparaginase, für die behandlung von hiv infektionen
EP1179012B2 (fr) 1999-05-17 2009-07-15 ConjuChem Biotechnologies Inc. Peptides hybrides inhibiteurs a action prolongee des infections virales
EP1235618A2 (fr) 1999-09-07 2002-09-04 Conjuchem, Inc. Diffusion pulmonaire permettant la bioconjugaison
AU2001289132A1 (en) * 2000-11-28 2002-06-11 Phoenix Pharmacologics, Inc. Modified arginine deiminase
HK1053577A2 (en) * 2002-06-20 2003-10-10 Bio-Cancer Treatment International Limited Pharmaceutical composition and method of treatment of human malignanices with arginine deprivation
US20060122583A1 (en) * 2002-06-25 2006-06-08 Glucon Inc Method and apparatus for performing myocardial revascularization
ES2477118T3 (es) * 2002-11-18 2014-07-15 Polaris Group Método para inhibir la replicaci�n viral in vivo
CN1997666A (zh) 2003-02-26 2007-07-11 印特缪恩股份有限公司 聚乙二醇修饰的干扰素组合物及其使用方法
CN1536079A (zh) * 2003-04-09 2004-10-13 上海复旦张江生物医药股份有限公司 修饰的精氨酸脱亚氨酶
JP2007530440A (ja) * 2003-05-12 2007-11-01 アフィーマックス・インコーポレイテッド 新規ポリ（エチレングリコール）修飾化合物およびその用途
BRPI0406605B8 (pt) 2003-11-13 2021-05-25 Hanmi Holdings Co Ltd conjugado de proteína, método para a preparação do mesmo e composição farmacêutica para intensificar a duração e estabilidade in vivo de um polipeptídeo fisiologicamente ativo
EP1699821B1 (fr) 2003-12-31 2012-06-20 Merck Patent GmbH PROTEINE HYBRIDE Fc-ERYTHROPOIETINE A PHARMACOCINETIQUE AMELIOREE
CN100355784C (zh) 2004-02-12 2007-12-19 江苏恒瑞医药股份有限公司 聚乙二醇修饰α－干扰素1b的制备方法
JP2005245269A (ja) 2004-03-03 2005-09-15 Nipro Corp 血清アルブミン多量体を含む遺伝子組換え型蛋白質
WO2005111072A2 (fr) 2004-04-29 2005-11-24 The Trustees Of Columbia University In The City Of New York Protéines hybrides de notch et leurs utilisations
CN1311867C (zh) 2004-09-27 2007-04-25 侯新朴 一种用于鼻腔给药的神经生长因子制剂

Also Published As

Publication number Publication date
EP1987838A1 (fr) 2008-11-05
CA2637687A1 (fr) 2007-07-26
CN101002945A (zh) 2007-07-25
US20100303893A1 (en) 2010-12-02
WO2007082482A1 (fr) 2007-07-26
JP2009523433A (ja) 2009-06-25
AU2007207267A1 (en) 2007-07-26
CA2637687C (fr) 2015-07-14
CN101002945B (zh) 2012-09-05
AU2007207267B2 (en) 2012-06-28
EP1987838B1 (fr) 2016-01-13
EP1987838A4 (fr) 2010-02-24
WO2007082482B1 (fr) 2007-09-07

Similar Documents

Publication Publication Date Title
MX2018008680A (es) Moleculas de union especifica a proteina de union a adn de respuesta transactiva de 43 kda (tdp-43).
WO2009063970A1 (fr) Diagnostic et traitement du cancer à l'aide d'un anticorps anti-gpr49
WO2010002862A3 (fr) Protéines se liant au récepteur 3 du facteur de croissance des fibroblastes (fgfr3)
BRPI0906435B8 (pt) Anticorpo anti-cd79b quimérico, composto conjugado, formulação farmacêutica, método para determinar a presença da proteína cd79b, ensaio para detectar células de câncer, método para inibir proliferação celular, usos de um anticorpo, de um composto conjugado e de uma formulação farmacêutica, e método para a fabricação de um composto conjugado
PH12016500658A1 (en) Human anti-alpha-synuclein autoantibodies
NZ599971A (en) Monoclonal antibodies to progastrin and their uses
TNSN08548A1 (en) Prlr-specific antibody and uses thereof
NO20082683L (no) Neuroendokrin tumorbehandling
ATE516301T1 (de) Y2-selektive rezeptoragonisten für therapeutische eingriffe
BR112012012911A2 (pt) métodos para triar uma molécula capaz de ligação a cd4, para produzir uma composição terapêutica, para triar um anticorpo ou fragmento de anticorpo, in vitro para a ativação de células t regulatórias cd4+cd25+, para tratar um indivíduo, e para triar a presença de células regulatórias t cd4+cd25+ em uma amostra, composição terapêutica, anticorpo ou fragmento de anticorpo, peptídeo isolado, mimótopo de um peptídeo isolado, ácido nucleico, vetor, célula hospedeira ou hibridoma, usos de um anticorpo ou fragmento de anticorpo, do peptídeo isolado e de uma célula t regulatória cd4+cd25+, célula t regulatória cd4+cd25+, e, kit.
Dantuluri et al. Proteome targets of ubiquitin‐like samp1ylation are associated with sulfur metabolism and oxidative stress in Haloferax volcanii
WO2010031749A9 (fr) Compositions et procédés pour détecter tlr3
WO2007115660A3 (fr) Procédé et dispositif de production d'engrais azotés à partir de substances biogènes
TW200626900A (en) Wnt proteins and detection and treatment of cancer
WO2008151200A3 (fr) Isoformes liés au cancer des composants des complexes de facteurs de transcription en tant que marqueurs biologiques et cibles de médicaments
WO2006034328A3 (fr) Proteines wnt et detection et traitement du cancer
WO2007067984A3 (fr) Anticorps neutralisants diriges contre le ligand psgl-1 de primate et utilisations a cet effet
WO2007062174A3 (fr) Dispositifs et procedes pour le repliage sous pression elevee de proteines
WO2008054431A3 (fr) Thérapies anti-hyperprolifératives ciblant des hdgf
Wu et al. Amino-substituted β-cyclodextrin copper (II) complexes for the electrophoretic enantioseparation of dansyl amino acids: Role of dual chelate–inclusion interaction and mechanism
Karunaratne et al. Conformational changes associated with post-translational modifications of Pro143 in Skp1 of Dictyostelium—a dipeptide model system
Yang et al. Dissolution of antibiotics mycelium in ionic liquids: Performance and mechanism
Kokuryo et al. Corrigendum to “SPIO-PICsome: Development of a highly sensitive and stealth-capable MRI nano-agent for tumor detection using SPIO-loaded unilamellar polyion complex vesicles (PICsomes)”[J. Control. Release, Volume 169 (2013) 220–227]
Tang Modeling Sensitivity to Antibody Drug Conjugates in Urothelial Cancer Using Patient-Derived Models
WO2006005621A3 (fr) Procede de fabrication de conjugues albumine/corticoides

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application